scholarly journals S707 Use of Systemic Steroids in the Management of Inflammatory Bowel Disease and Its Effects on Intraocular Pressure

2021 ◽  
Vol 116 (1) ◽  
pp. S321-S322
Author(s):  
Amrik Gill ◽  
Uni Wong ◽  
Abigail R. Noyes ◽  
Ramya Swamy
Keyword(s):  
Inflammatory Bowel Disease ◽  
Intraocular Pressure ◽  
Bowel Disease ◽  
Systemic Steroids ◽  
Inflammatory Bowel

scholarly journals P095 Unusual side effects of systemic steroids in children with inflammatory bowel disease

2019 ◽  
Vol 114 (1) ◽  
pp. S25-S25 ◽  
Author(s):  
Maheshwari Anshu ◽  
Kang Ian ◽  
Yaseen Mohammad ◽  
Lowrance Christina
Keyword(s):  
Inflammatory Bowel Disease ◽  
Side Effects ◽  
Bowel Disease ◽  
Systemic Steroids ◽  
Inflammatory Bowel

Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure

1992 ◽  
Vol 102 (6) ◽  
pp. 1957-1961 ◽  
Author(s):  
Ramesh C. Tripathi ◽  
Barbara S. Kirschner ◽  
Michael Kipp ◽  
Brenda J. Tripathi ◽  
David Slotwiner ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Intraocular Pressure ◽  
Bowel Disease ◽  
Pediatric Patients ◽  
Corticosteroid Treatment ◽  
Inflammatory Bowel

scholarly journals Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study

2021 ◽  
Vol 10 (13) ◽  
pp. 2885
Author(s):  
María Chaparro ◽  
Ana Garre ◽  
Andrea Núñez Ortiz ◽  
María Diz-Lois Palomares ◽  
Cristina Rodríguez ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Characteristics ◽  
Large Scale ◽  
Population Based ◽  
First Year ◽  
Systemic Steroids ◽  
Drug Treatments ◽  
Inflammatory Bowel ◽  
Incident Cases

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31–56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.

scholarly journals An Analysis of an Inflammatory Bowel Disease Practise in an Urban Community Hospital

2000 ◽  
Vol 14 (6) ◽  
pp. 483-488 ◽  
Author(s):  
David Adam ◽  
Jonathan Adam ◽  
Howard Price
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Small Bowel ◽  
Bowel Disease ◽  
Community Hospital ◽  
Age Of Onset ◽  
Urban Community ◽  
Benign Disease ◽  
Systemic Steroids ◽  
Inflammatory Bowel

OBJECTIVES: To review an individual community gastroenterologist’s experience with inflammatory bowel disease (IBD). The aspects studied were distribution of disease, need for hospital admission, immunosuppressants, systemic steroids, and surgery and its indications. The incidence of cancer was also reviewed.PATIENTS AND METHODS: The charts of all IBD patients (n=373) seen between 1993 and 1996 by an individual gastroenterologist in an urban community hospital were reviewed for the aforementioned information. Patients seen during this period may have been diagnosed with IBD before or during the period of 1993 to 1996.RESULTS: Of the 373 patients, 219 had Crohn’s disease (CD) and 154 had ulcerative colitis (UC). The most common age of onset for both groups was 20 to 29 years. Distal UC and distal Crohn’s colitis patients rarely required surgery, hospitalization, systemic steroids or immunosuppressants. Eighty per cent of patients with small bowel CD and 51% of those with ileocolonic CD required at least one operation. Of the UC patients, 10.4% required surgery. Of the UC patients undergoing surveillance for cancer, none developed cancer but one developed significant dysplasia.CONCLUSIONS: In both CD and UC the site of the inflammation plays a major role in determining the need for hospitalization, surgery, systemic steroids and immunosuppressants. Distal UC, the most common form of UC in this group of patients, is a very benign disease. Of all forms of IBD, small bowel CD had the greatest need for hospitalization, surgery and systemic steroids.

scholarly journals Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients

2019 ◽  
Vol 14 (4) ◽  
pp. 480-489 ◽  
Author(s):  
Elena Eliadou ◽  
Joana Moleiro ◽  
Davide Giuseppe Ribaldone ◽  
Marco Astegiano ◽  
Katja Rothfuss ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Lung Disease ◽  
Bowel Disease ◽  
European Respiratory Society ◽  
Drug Induced ◽  
Systemic Steroids ◽  
Causative Drug ◽  
Granulomatous Lung Disease ◽  
Inflammatory Bowel ◽  
Almost All

Abstract Background Interstitial lung [ILD] disease and granulomatous lung disease [GLD] are rare respiratory disorders that have been associated with inflammatory bowel disease [IBD]. Clinical presentation is polymorphic and aetiology is unclear. Methods This was an ECCO-CONFER project. Cases of concomitant ILD or GLD and IBD, or drug-induced ILD/GLD, were collected. The criteria for diagnosing ILD and GLD were based on definitions from the American Thoracic Society and the European Respiratory Society and on the discretion of reporting clinician. Results We identified 31 patients with ILD. The majority had ulcerative colitis [UC] [n = 22]. Drug-related ILD was found in 64% of these patients, 25 patients [80.6%] required hospitalisation, and one required non-invasive ventilation. The causative drug was stopped in all drug-related ILD, and 87% of patients received systemic steroids. At follow-up, 16% of patients had no respiratory symptoms, 16% had partial improvement, 55% had ongoing symptoms, and there were no data in 13%. One patient was referred for lung transplantation, and one death from lung fibrosis was reported. We also identified 22 GLD patients: most had Crohn’s disease [CD] [n = 17]. Drug-related GLD was found in 36% of patients and 10 patients [45.4%] required hospitalisation. The causative drug was stopped in all drug-related GLD, and 81% of patients received systemic steroids. Remission of both conditions was achieved in almost all patients. Conclusions ILD and GLD, although rare, can cause significant morbidity. In our series, over half of cases were drug-related and therefore focused pharmacovigilance is needed to identify and manage these cases.

Disease severity predicts bone loss: A longitudinal study in inflammatory bowel disease patients

2001 ◽  
Vol 120 (5) ◽  
pp. A628-A628
Author(s):  
S HENDERSON ◽  
S DHALIWAL ◽  
N HOFFMAN ◽  
R PRINCE
Keyword(s):  
Inflammatory Bowel Disease ◽  
Longitudinal Study ◽  
Bone Loss ◽  
Disease Severity ◽  
Bowel Disease ◽  
Inflammatory Bowel

Low bone mineral density in association with increased bone resorbtion in patient with inflammatory bowel disease at diagnosis

2001 ◽  
Vol 120 (5) ◽  
pp. A628-A628
Author(s):  
T WONG ◽  
D SMITH ◽  
D SIMPSON ◽  
A COAKLEY ◽  
C MONIZ ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Inflammatory Bowel Disease ◽  
Bone Mineral ◽  
Bowel Disease ◽  
Mineral Density ◽  
Low Bone Mineral Density ◽  
Inflammatory Bowel

6-Mercaptopurine metaboline profile is optimized by azathioprine formulation and non-use of 5-aminosalicylic acid angents in patients with inflammatory bowel disease

2001 ◽  
Vol 120 (5) ◽  
pp. A625-A625 ◽  
Author(s):  
T STEVENS ◽  
J ACHKAR ◽  
A BRZEZINSKI ◽  
D SEIDNER ◽  
B LASHNER
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Aminosalicylic Acid ◽  
Inflammatory Bowel
Sign in / Sign up

Export Citation Format

Share Document